LAUNXP Biomedical , Ltd Total Liabilities

LAUNXP Biomedical , Ltd (6876.TWO) currently reports a total liabilities of $140M as of June 2026. That compares with $280M in the prior-year period — down 50.4% year over year. Use the charts on this page to explore LAUNXP Biomedical , Ltd's total liabilities history and peer comparisons.

LAUNXP Biomedical , Ltd's total liabilities decreased from $280M to $140M — a 50.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

LAUNXP Biomedical , Ltd reported $140M in total liabilities as of June 2026. That compares with $280M in the prior-year period — down 50.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $140M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for LAUNXP Biomedical , Ltd, and consider following 6876.TWO for alerts when major investors trade the stock.

LAUNXP Biomedical , Ltd is classified in the Healthcare sector. On total liabilities, it currently shows $140M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 6876.TWO with unrelated industries.